HOME >> MEDICINE >> NEWS
Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder

isodes associated with overactive bladder.

Since its introduction in January 2001, DETROL LA has become the number one prescribed treatment for overactive bladder in the United States and has been prescribed for more than seven million patients worldwide.

DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency and frequency.

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Patients with the following conditions should be treated with caution: renal impairment, bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic function. Dry mouth was the most frequently reported adverse event (DETROL LA 23 percent vs. placebo 8 percent); others (> 4 percent) included headache (DETROL LA 6 percent vs. placebo 4 percent), constipation (DETROL LA 6 percent vs. placebo 4 percent), and abdominal pain (DETROL LA 4 percent vs. placebo 2 percent).


'"/>


13-Dec-2004


Page: 1 2 3

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
3. Long-term obesity linked to loss of brain tissue in women
4. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
5. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
6. Long-term use of antibiotics possibly linked with increased risk of breast cancer
7. Long-term follow-up of mortality in patients with community-acquired pneumonia
8. Long-term outcome of epilepsy surgery is favorable for many
9. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
10. Long-term avoidance of milk in children results in poor bone health
11. Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... ... It is vital for any lab to secure funding, and the best ... Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline analysis and ... a GLP (Good Laboratory Practice) fashion. , With features designed to simplify life in ...
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward ... comments on social media that offer a rare glimpse into the mind of those ... and New York Times bestselling author, has described people with ADHD as having “Ferrari ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood associated ... appearing online in the journal Radiology. , Heart disease and brain disease exact a ... the rapidly aging population. Damage to both organs often occurs at a subclinical stage, ...
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Arcturus ... RNA medicines company, announced today that it entered ... develop RNA-based therapeutics for the treatment of NASH ... wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer ... "Given Takeda,s long-standing commitment to and expertise ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
(Date:12/6/2016)... new study released today by the Alliance for Integrity ... Pricing Program will continue to expand at an unprecedented rate ... $23 billion in total purchases at the 340B price. This ... B drug reimbursement purchases over the next five years.      ... data on total drug purchases through 340B from 2005 to ...
Breaking Medicine Technology:
Cached News: